Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1833-1836

  Stephan, Carsten ^a   Meyer, Hellmuth Alexander ^a   Paul, Eva Maria ^a   Kristiansen, Glen ^a   Loening, Stefan A ^a   Lein, Michael ^a   Jung, Klaus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

proPSA; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34250755340     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Polascik TJ, Oesterling JE and Partin AW: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162: 293-306, 1999.
2. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M and Loening SA: Prostate specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 59: 2-8, 2002.
3. Mikolajczyk SD, Marks LS, Partin AW and Rittenhouse HG: Free prostate-specific antigen in serum is becoming more complex. Urology 59: 797-802, 2002.
4. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL and Saedi MS: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50: 710-714, 1997.
5. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, Evans CL, Gasior CL, Linton HJ, Carpenter P and Rittenhouse HG: A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61: 6958-6963, 2001.
6. Peter J, Unverzagt C, Krogh TN, Vorm O and Hoesel W: Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61: 957-962, 2001.
7. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, Klocker H and Mikolajczyk SD: Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171: 2239-2244, 2004.
8. Hoesel W, Peter J and Hübel-Parajsz C: Development and evaluation of an ELISA for the measurement of proPSA forms in sera. Anticancer Res 22: 529, 2002.
9. Bangma CH, Wildhagen MF, Yurdakul G, Schroder FH and Blijenberg BG: The value of (-7, -5) pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 93: 720-724, 2004.
10. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, Haese A, Chun F, Schnorr D, Loening SA and Jung K: A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 174: 2150-2153, 2005.
11. Kairisto V and Poola A: Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest 55(Suppl 222): 43-60, 1995.
12. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, Katir D, Amirkhan A and Rittenhouse HG: Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50: 1017-1025, 2004.
13. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, Horninger W, Klocker H and Mikolajczyk SD: Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170: 2181-2185, 2003.